From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 ...
You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...
An international research team has uncovered compelling evidence that gut-microbe-derived molecules may play an important ...
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) ...
Water-soluble polymers conjugated to proteins and anticancer drugs are in routine clinical use and clinical development as both single agents and components of combination therapy. This is ...
Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...
NEW YORK, February 24, 2025--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, ...
The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...
In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports. In the recent years, antibody-drug conjugates (ADC) have been gradually gaining ...
Genitourinary oncologist Jonathan Rosenberg says two newer classes of bladder cancer drugs are greatly expanding treatment options for the disease. Promising new drugs have begun to transform the ...
Biopharmaceutics is a rapidly growing research field that aims at producing viable therapeutic and prophylactic treatments for many diseases. The use of biological therapies has increased ...